Company Exicure Inc Other OTC
Equities
US30205M1018
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Immuno-oncology Therapeutics
100.0
%
| 0 | 100.0 % | 29 | 100.0 % | -6,068.12% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 29 | 100.0 % | -6,068.12% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Kang
CEO | Chief Executive Officer | 63 | 24/23/24 |
Ji-Young Hwang
DFI | Director of Finance/CFO | 47 | 01/22/01 |
Investor Relations Contact | 47 | - | |
Joshua Miller
AUD | Comptroller/Controller/Auditor | 48 | 01/22/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ji-Young Hwang
DFI | Director of Finance/CFO | 47 | 01/22/01 |
Paul Kang
CEO | Chief Executive Officer | 63 | 24/23/24 |
Hyuk Joon Ko
BRD | Director/Board Member | - | 23/23/23 |
Dongho Lee
BRD | Director/Board Member | - | 21/23/21 |
Hojoon Lee
BRD | Director/Board Member | - | 23/23/23 |
Minhee Eom
BRD | Director/Board Member | - | 26/23/26 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 8,648,307 | 4,753,248 ( 54.96 %) | 0 | 54.96 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+5.33% | 11TCr | |
+12.11% | 11TCr | |
-12.56% | 2.22TCr | |
-3.32% | 2.13TCr | |
-5.85% | 1.9TCr | |
-35.21% | 1.85TCr | |
-10.86% | 1.68TCr | |
+37.57% | 1.25TCr | |
-26.24% | 808.97Cr |